Quantcast

Cambridge Healthtech Associates™ and Nucro-Technics Announce Results of Market Research Investigation

August 15, 2012

Research indicates increased use of toxicology testing throughout R&D lifecycle.

Needham, MA and Scarborough, Ontario (PRWEB) August 14, 2012

Cambridge Healthtech Associates (CHA), the organizers of the Drug Safety Executive Council , and Nucro-Technics, a full-service Contract Support Organization, today announced the results of a survey focused on a market evaluation of a new biomarker tool to predict adverse events. The goal of this market research project was to provide industry feedback on a novel fee-for-service assay for use in the evaluation of the potential toxicity of new drug candidates.

“One potentially highly significant outcome from this survey is the acceleration of a trend for drug development companies to use toxicology testing throughout all stages of the drug R&D process, starting from discovery,” said Bedrich Videl, Special Projects, at Nucro-Technics, “as this trend accelerates, it could result in significant decreases in drug development costs and time-to-market for the entire industry.”

CHA conducted interviews with leaders in the pharmaceutical and biotech industries to gain an understanding of the current market landscape in drug safety biomarkers, assess the market needs and priorities on drug safety and biomarkers, and examine how the safety screening field is evolving.

“Another significant outcome is that the scientific community increasingly recognizes the benefits of using a combination of Systems Biology and biomarkers to predict toxicity, especially hepatotoxicity,” said Dr. Renato Cardoso, Senior Research Scientist, at Nucro-Technics.

“We have successfully completed this research project, and as with all such studies, there is wide confirmation and a few surprises,” said Dr. Ernie Bush, Scientific Director, at Cambridge Healthtech Associates and the Drug Safety Executive Council. “Helping clients like Nucro-Technics assess the market´s interest in drug safety biomarkers is essential to understanding the status of this technology, and the optimal ways of moving forward to gain benefit for the pharma industry and patient health.”

About Cambridge Healthtech Associates

Cambridge Healthtech Associates (CHA) uses its unique collaborative model to improve the speed, economics and effectiveness of life science research and development, leveraging its consulting, technology evaluations and communities to help clients in the industry penetrate the marketplace and increase revenue. Read more at http://www.chacorporate.com.

Cambridge Healthtech Associates also manages the Drug Safety Executive Council (DSEC) a community of drug safety professionals focused on the development of better and safer medicines and can be found at http://www.drugsafetycouncil.org.

About Nucro-Technics

Nucro-Technics is a full-service Pharmaceutical Contract Support Organization that has completed projects for the ten largest pharmaceutical companies worldwide. Nucro-Technics´ in-house services include: Pre-Clinical Toxicology; Genetic Toxicology; Bioanalytical Services; Chemistry/Microbiology Analysis & Method Development; and Quality Control/Quality Assurance/Regulatory Affairs consulting to the biotech, pharmaceutical and medical device industries. Read more at http://www.nucro-technics.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/8/prweb9759686.htm


Source: prweb



comments powered by Disqus